• 1. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 2. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400

Recent Advances in the Application of tert-Butyl 3-Ethylpiperidine-3-Carboxylate (CAS: 1339626-73-1) in Chemical Biology and Pharmaceutical Research

The compound tert-butyl 3-ethylpiperidine-3-carboxylate (CAS: 1339626-73-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications as a key intermediate in the synthesis of bioactive molecules. This research briefing aims to provide an overview of the latest advancements involving this compound, focusing on its synthetic utility, pharmacological potential, and emerging applications in drug discovery.

Recent studies have highlighted the role of tert-butyl 3-ethylpiperidine-3-carboxylate as a crucial building block in the synthesis of novel piperidine derivatives, which are widely recognized for their pharmacological properties. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated its use in the development of selective serotonin reuptake inhibitors (SSRIs) with improved blood-brain barrier permeability. The compound's unique structural features, including the tert-butyl ester group and the ethyl substitution at the 3-position, contribute to its stability and reactivity, making it an attractive candidate for further derivatization.

In addition to its synthetic applications, tert-butyl 3-ethylpiperidine-3-carboxylate has been investigated for its potential as a scaffold in fragment-based drug design. A recent preprint on bioRxiv (2024) described its incorporation into a library of fragments targeting G protein-coupled receptors (GPCRs). The study utilized computational docking and molecular dynamics simulations to predict binding affinities, followed by experimental validation using surface plasmon resonance (SPR) assays. The results indicated that derivatives of this compound exhibit promising interactions with specific GPCR subtypes, suggesting its utility in the development of new therapeutics for neurological disorders.

Furthermore, advancements in catalytic methodologies have enabled more efficient and sustainable synthesis routes for tert-butyl 3-ethylpiperidine-3-carboxylate. A 2024 publication in ACS Catalysis reported a novel asymmetric hydrogenation protocol using chiral iridium catalysts, achieving high enantioselectivity (up to 98% ee) and yield (92%). This methodological breakthrough addresses previous challenges associated with the stereoselective synthesis of this compound, thereby facilitating its broader application in enantioselective drug development.

In conclusion, tert-butyl 3-ethylpiperidine-3-carboxylate (CAS: 1339626-73-1) continues to play a pivotal role in chemical biology and pharmaceutical research, with recent studies underscoring its synthetic versatility, pharmacological potential, and methodological advancements. Future research directions may include exploring its applications in targeted drug delivery systems and investigating its biological activities in preclinical models. These developments highlight the compound's enduring relevance in the pursuit of innovative therapeutic solutions.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)